AXIM - AXIM Biotechnologies, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

AXIM Biotechnologies, Inc.

45 Rockefeller Plaza
20th Floor Suite 83
New York, NY 10111
United States

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. George E. AnastassovFounder & Chairman595kN/A1963
Mr. John W. Huemoeller IIPres, CEO & Director45kN/A1955
Mr. Robert T. MalasekCFO & Sec.247kN/A1968
Mr. Lekhram ChangoerCTO & Director475kN/A1967
Dr. Philip A. Van Damme D.M.D., M.D., DMD, MD, Ph.D.Chief Medical Officer & Director45kN/A1953
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. Axim Biotechnologies, Inc. was formerly known as Axim International Inc. and changed its name to Axim Biotechnologies, Inc. in July 2014. The company was founded in 2010 and is headquartered in New York, New York.

Corporate Governance

AXIM Biotechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.